JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S10

Parkinson's Disease: Neurotransmitter Imbalance, Motor Dysfunction, and Nursing Interventions for Quality of Life

Manal Dhaher Saqer Alanazi[1], Hind Abdulrahman Ahmed Al Ateeq[2], Amira Barrak Aldhefri[3], Abeer Hussin Alanazi[3], Mansour Ayidh Awadh Almutairi[4], Abdulaziz Mohammed A Almogamas[5], Ali Yahya Al-Qahtani[6], Hussain Ali Khabrani[7]

1. Ksa, ministry of health, Primary Health Care Center, Alsahafa
2. Ksa, ministry of health, Eradah Complex for Mental Health
3. Ksa, ministry of health, Maternity and Children's
4. Ksa, ministry of health, Hospital management
5. Ksa, King Khalid International Airport Health Monitoring Center.
6. Ksa, ministry of health, Al-Iman General Hospital
7. Ksa, King Khalid University Hospital

ABSTRACT

Background: Parkinson’s Disease (PD) is a progressive neurodegenerative condition predominantly marked by motor symptoms, including bradykinesia, stiffness, tremor, and postural instability, with non-motor symptoms such as cognitive impairment, mood disorders, and autonomic dysfunction. The etiology of Parkinson's Disease is intricately linked to neurotransmitter imbalances, namely the reduction of dopamine due to the death of dopaminergic neurons in the substantia nigra. This imbalance disturbs the basal ganglia pathways, essential for motor control and coordination. Dysfunction in serotonergic, noradrenergic, and cholinergic pathways also exacerbates non-motor symptoms, further diminishing patients' quality of life. Notwithstanding progress in comprehending the condition, care predominantly remains symptomatic, emphasizing the enhancement of functionality and quality of life by pharmaceutical and non-pharmacological methods. Aim: This study aims to provide an exhaustive analysis of the molecular mechanisms that contribute to neurotransmitter imbalances in Parkinson's Disease and its clinical manifestations, especially motor dysfunction. It additionally aims to find and study evidence-based nursing interventions that tackle these difficulties and improve patients' quality of life. Methods: The study consolidates contemporary research and clinical guidelines about Parkinson’s Disease, emphasizing the significance of neurotransmitters in its development. It also examines the efficacy of nursing interventions in addressing both motor and non-motor complaints. The review encompasses medication adherence strategies, patient education, rehabilitation methods, and psychosocial support, highlighting the nurse's role in providing comprehensive care. Results: The results indicate that although dopamine depletion is fundamental to the pathophysiology of Parkinson's Disease, disturbances in serotonergic, noradrenergic,

and cholinergic systems considerably influence the variability of symptoms. Evidence-based nursing interventions, including as medication management, mobility training, cognitive support, and caregiver education, are crucial in alleviating symptom severity and averting consequences. Moreover, interdisciplinary strategies that include physical therapy, nutritional modifications, and psychosocial therapies have demonstrated efficacy in enhancing patient outcomes and fostering a sense of autonomy. Conclusion: Parkinson's Disease exhibits a multifaceted interaction of motor and non-motor symptoms caused by neurotransmitter abnormalities. Confronting these difficulties necessitates a multidisciplinary strategy, with nurses assuming a pivotal role in delivering patient-centered care. Effective nursing interventions decrease symptom load and promote patients' quality of life and functional independence. Future research should concentrate on investigating innovative therapy approaches aimed at non-dopaminergic systems and formulating sophisticated nursing practices to meet the changing requirements of patients with Parkinson's Disease.

KEYWORDS: Parkinson's Disease, neurotransmitter imbalance, dopamine, motor dysfunction, nursing interventions, quality of life, holistic care, multidisciplinary approach.

1. Introduction

Parkinson's disease (PD) is a degenerative neurological disorder first described by James Parkinson in 1817 as "Shaking Palsy." The individuals affected suffer a significant deterioration in their quality of life due to a combination of motor and non-motor symptoms inherent to this disorder. Bradykinesia, rigidity, resting tremor, and postural instability are characteristic motor symptoms of Parkinson's disease. Conversely, non-motor symptoms encompass cognitive deterioration, emotional disorders, sleep abnormalities, and autonomic dysfunction [2, 3].

Epidemiological studies indicate that Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder, behind Alzheimer's disease, with an estimated global prevalence exceeding 6 million individuals. The incidence of Parkinson's disease (PD) increases with age, often manifesting between 55 and 65 years, and is marginally more common in males than in girls [5]. The disorder imposes a substantial financial strain on healthcare systems and society at large. This burden is associated with direct medical expenses, diminished productivity, and the necessity for prolonged rehabilitation [6].

The etiology of Parkinson's disease (PD) primarily involves the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to a significant reduction in dopamine levels in the striatal region. The deficiency of dopamine disrupts the circuitry of the basal ganglia, resulting in the characteristic motor signs of the illness [8]. Moreover, an increasing corpus of evidence indicates that non-dopaminergic systems, including serotonergic, noradrenergic, and cholinergic pathways, have a role in the etiology of Parkinson's disease (PD), hence contributing to its many clinical presentations [9, 10].

Despite extensive research, the etiology of Parkinson's disease remains incompletely understood. Parkinson's disease is widely recognized as the outcome of a complex

interplay between genetic and environmental factors. Genetic mutations account for around 5-10% of familial cases of Parkinson's disease. The mutations encompass those identified in the SNCA, LRRK2, and PARK2 genes. Environmental exposures, including pesticides, heavy metals, and residence in rural regions, have been associated with a heightened risk of developing Parkinson's disease (PD), although the evidence establishing a direct correlation remains inconclusive [12].

The management of Parkinson's disease (PD) encompasses diverse strategies aimed at alleviating symptoms and improving quality of life. Levodopa, dopamine agonists, and monoamine oxidase-B inhibitors exemplify the categories of drugs utilized in pharmacological therapies. The main objective of these therapies is to rehabilitate dopaminergic function [13]. However, these treatments are often associated with motor impairments and may inadequately address symptoms unrelated to motor function. Non-pharmaceutical rehabilitation therapies, including speech therapy, occupational therapy, and physical therapy, are crucial in managing Parkinson's disease (PD), especially for addressing motor dysfunction and enhancing functional independence [14].

Nursing workers are a vital element of the multidisciplinary care team for individuals with Parkinson's disease (PD). They are tasked with provide comprehensive care that include medication management, education for patients and caregivers, and the formulation of personalized care plans [15]. Their tasks encompass monitoring the condition's progression, managing symptoms, and facilitating access to resources and support services.

This review focuses on motor dysfunction and aims to elucidate the molecular processes responsible for neurotransmitter imbalances linked to Parkinson's disease and its clinical manifestations. Additionally, it seeks to identify and examine evidence-based nursing interventions that address these issues to enhance the quality of life for patients with Parkinson's disease (PD).

Figure 1 Parkinsonism Symptoms

Neurotransmitter Imbalance in Parkinson's Disease

Parkinson's Disease (PD) is a multifaceted neurodegenerative disorder characterized

by a progressive decline in motor and non-motor functions. Central to its pathophysiology is the disruption of neurotransmitter systems, notably the dopaminergic pathways, which play a pivotal role in motor control and various neuropsychiatric functions.

Role of Dopamine

The hallmark of PD is the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), a critical component of the midbrain. This neuronal loss leads to a significant reduction in dopamine levels within the striatum, a key region involved in regulating movement [16]. The depletion of dopamine disrupts the normal functioning of the basal ganglia circuitry, resulting in the characteristic motor symptoms of PD, such as bradykinesia, rigidity, tremor, and postural instability [17].

The basal ganglia, comprising structures like the striatum, globus pallidus, subthalamic nucleus, and substantia nigra, are integral to motor control. Dopamine modulates the activity of these nuclei, facilitating the initiation and smooth execution of voluntary movements. In PD, the loss of dopaminergic input leads to an imbalance between the direct and indirect pathways of the basal ganglia, culminating in motor dysfunction [18].



Figure 2 the Earliest Sign of Parkinson's disease

Other Neurotransmitters

While dopaminergic dysfunction is central to PD, alterations in other neurotransmitter systems also contribute to the disease's complex symptomatology.

Serotonergic Dysfunction and Mood Disorders

The serotonergic system, originating primarily from the raphe nuclei, is implicated in mood regulation. In PD, degeneration of serotonergic neurons has been observed, contributing to non-motor symptoms such as depression and anxiety [19]. Studies have demonstrated reduced serotonin transporter binding in PD patients, correlating with depressive symptoms [20].

Noradrenergic Pathways and Autonomic Symptoms

The locus coeruleus, the brain's primary source of noradrenaline, undergoes

degeneration in PD. This loss affects autonomic functions, leading to symptoms like orthostatic hypotension, urinary incontinence, and gastrointestinal disturbances [21]. Noradrenergic dysfunction also contributes to cognitive deficits and mood disturbances observed in PD patients [22].

Cholinergic Deficits and Cognitive Impairments

Cholinergic neurons, particularly those in the nucleus basalis of Meynert, are crucial for cognitive functions. In PD, cholinergic deficits have been linked to cognitive impairments, including attention deficits and dementia [23]. The reduction in acetylcholine levels exacerbates motor symptoms and contributes to gait disturbances and falls [24].

Biochemical Markers

Identifying biomarkers for PD is essential for early diagnosis and monitoring disease progression. Biochemical markers, such as α-synuclein aggregates, dopamine metabolites, and inflammatory cytokines, have been investigated for their potential to reflect disease status and therapeutic response [25]. Advancements in neuroimaging and cerebrospinal fluid analysis have provided insights into the biochemical alterations in PD, aiding in the development of targeted therapies [26].

Pathophysiological Mechanisms

The etiology of PD involves a complex interplay of genetic, environmental, and molecular factors.

Oxidative Stress

Oxidative stress, resulting from an imbalance between reactive oxygen species production and antioxidant defenses, leads to neuronal damage. In PD, oxidative stress contributes to the degeneration of dopaminergic neurons, exacerbating disease progression [27].

Neuroinflammation

Chronic neuroinflammation, characterized by the activation of microglia and astrocytes, plays a role in PD pathogenesis. Elevated levels of pro-inflammatory cytokines have been detected in the brains of PD patients, indicating an ongoing inflammatory response that may contribute to neuronal loss [28].

Genetic Factors

Genetic mutations, such as those in the SNCA, LRRK2, and PARK2 genes, have been associated with familial forms of PD. These mutations affect protein aggregation, mitochondrial function, and cellular homeostasis, leading to neuronal vulnerability and degeneration [29].

Understanding the multifaceted neurotransmitter imbalances and underlying pathophysiological mechanisms in PD is crucial for developing effective therapeutic strategies aimed at alleviating symptoms and slowing disease progression.

Motor Dysfunction in Parkinson's Disease

Parkinson's Disease (PD) is primarily characterized by a spectrum of motor dysfunctions that significantly impair patients' quality of life. These motor symptoms are the most recognizable manifestations of the disease and are pivotal in its diagnosis and management.

Clinical Presentation

The cardinal motor symptoms of PD include bradykinesia, rigidity, tremor, and postural instability.

Bradykinesia: This refers to the slowness of movement and is considered the most characteristic feature of PD. Patients often experience difficulty initiating movements and may exhibit a reduction in spontaneous movements, such as facial expressions, leading to a masked facies [32].

Rigidity: Muscle stiffness is another hallmark of PD, presenting as increased resistance to passive movement. This rigidity can affect all muscle groups and contributes to the decreased range of motion and discomfort experienced by patients [33].

Tremor: Typically, PD is associated with a resting tremor, often described as "pill-rolling," which usually begins unilaterally in the hands but can progress to involve other parts of the body. Interestingly, not all PD patients exhibit tremor, and its absence does not exclude the diagnosis [34].

Postural Instability: As the disease progresses, patients may develop balance impairments, leading to an increased risk of falls. This symptom is often less responsive to dopaminergic therapies and poses significant challenges in patient care [35].

Pathophysiology of Motor Symptoms

The motor symptoms of Parkinson's disease are mainly due to the destruction of dopaminergic neurons in the substantia nigra pars compacta, resulting in a substantial decrease in striatal dopamine levels. The dopaminergic deficiency impairs the proper operation of the basal ganglia circuits, which are essential for the regulation of voluntary movements [36].

The basal ganglia comprise interconnected nuclei, namely the striatum, globus pallidus, subthalamic nucleus, and substantia nigra. Dopamine, in a healthy condition, regulates the equilibrium between the direct and indirect pathways in the basal ganglia, so fostering smooth and coordinated motions. In Parkinson's disease, the depletion of dopaminergic input causes hyperactivity of the indirect pathway and hypoactivity of the direct pathway, leading to the suppression of thalamocortical projections and, subsequently, the motor symptoms exhibited by patients [37].

Moreover, non-dopaminergic systems, including cholinergic, serotonergic, and noradrenergic pathways, are impacted in Parkinson's disease, influencing both motor and non-motor symptoms. The participation of these systems highlights the intricacy of Parkinson's disease pathogenesis and the difficulties in its management [38].



Figure 3 Parkinson's disease

Assessment Tools

Accurate assessment of motor dysfunction in PD is essential for diagnosis, monitoring disease progression, and evaluating therapeutic responses.

Unified Parkinson's Disease Rating Scale (UPDRS): The UPDRS is a comprehensive tool widely used to assess the severity and progression of PD. It comprises multiple sections evaluating mentation, behavior, mood, activities of daily living, motor

examination, and complications of therapy. The motor examination section specifically assesses bradykinesia, rigidity, tremor, and postural stability, providing a standardized measure of motor impairment [39].

Other Diagnostic Measures: In addition to the UPDRS, several other scales and tools are utilized in the assessment of PD motor symptoms:

- Hoehn and Yahr Scale: This scale stages PD progression based on motor function and balance, ranging from stage 1 (unilateral involvement) to stage 5 (wheelchair-bound or bedridden) [40].
- Timed Up and Go Test (TUG): This functional test measures the time taken for a patient to rise from a chair, walk a short distance, turn, return, and sit down, providing insights into mobility and balance [41].
- Gait Analysis: Quantitative assessment of gait parameters, such as stride length and walking speed, can help evaluate the extent of motor impairment and the effectiveness of interventions [42].

These assessment tools are integral in the comprehensive evaluation of PD, facilitating tailored therapeutic strategies and monitoring disease progression.

Nursing Interventions in Parkinson’s Disease

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that significantly impact patients' quality of life. Nursing interventions play a pivotal role in managing these symptoms, enhancing patient outcomes, and providing comprehensive care.

Medication Management

Ensuring Adherence to Dopaminergic Therapies

Adherence to prescribed dopaminergic medications, such as Levodopa and dopamine agonists, is crucial for symptom control in PD patients. Nurses are instrumental in educating patients about the importance of medication schedules, potential side effects, and the necessity of consistent drug intake to maintain therapeutic efficacy [43]. Implementing strategies like medication reminders and simplifying dosing regimens can improve adherence rates [44].

Managing Side Effects

Dopaminergic therapies often lead to side effects, including dyskinesia and motor fluctuations. Nurses monitor patients for these adverse effects and collaborate with healthcare providers to adjust dosages or introduce adjunct therapies as needed [45]. Patient education on recognizing early signs of side effects and reporting them promptly is essential for timely intervention [46].

Mobility and Fall Prevention

Physical Therapy Techniques and Assistive Devices

Nurses coordinate with physical therapists to develop individualized exercise programs aimed at improving strength, balance, and mobility. The use of assistive

devices, such as canes or walkers, is encouraged to enhance safety during ambulation [47]. Regular assessments of mobility status allow for timely modifications to the care plan [48].

Education on Safe Ambulation and Home Modifications

Educating patients and caregivers about safe walking techniques and the importance of removing home hazards reduces fall risk. Recommendations may include installing grab bars, ensuring adequate lighting, and rearranging furniture to create clear pathways [49]. Such interventions are vital in preventing injuries and promoting independence [50].

Psychosocial Support

Addressing Depression, Anxiety, and Social Isolation

PD patients frequently experience depression and anxiety, contributing to social withdrawal. Nurses assess mental health status and provide counseling or referrals to mental health professionals as appropriate [51]. Encouraging participation in support groups and community activities fosters social engagement and emotional well-being [52].

Facilitating Caregiver Support Networks

Recognizing the challenges faced by caregivers, nurses offer education on disease progression, symptom management, and self-care strategies. Facilitating access to respite care and support groups helps alleviate caregiver burden and promotes sustained caregiving capacity [53].

Nutrition and Lifestyle

Dietary Adjustments to Enhance Medication Absorption

Certain dietary components can affect the absorption of PD medications. Nurses educate patients on timing protein intake to avoid interference with Levodopa absorption and recommend diets rich in fiber to combat constipation, a common PD symptom [54]. Hydration status is also monitored to prevent dehydration and support overall health [55].

Role of Exercise in Neuroprotection and Symptom Management

Regular physical activity has been shown to improve motor function and may have neuroprotective effects. Nurses encourage patients to engage in exercises tailored to their abilities, such as walking, swimming, or tai chi, and provide guidance on maintaining a consistent exercise routine [56]. Collaborating with physical therapists ensures exercises are safe and effective [57].

Cognitive and Communication Interventions

Strategies for Managing Cognitive Decline

Cognitive impairments are common in PD. Nurses implement cognitive stimulation activities and provide strategies to enhance memory and executive function, such as using calendars, lists, and structured routines [58]. Monitoring cognitive changes

allows for timely interventions and support [59].

Speech Therapy

Speech difficulties, including hypophonia and dysarthria, affect communication. Nurses refer patients to speech-language therapists and reinforce techniques learned during therapy sessions, such as voice exercises and articulation practices, to improve speech clarity [60]. Encouraging the use of alternative communication methods, like writing or electronic devices, can also be beneficial [61].

Palliative Care and Advanced Stages

End-of-Life Care Considerations

In advanced PD stages, palliative care focuses on symptom relief and quality of life. Nurses assess and manage pain, respiratory difficulties, and other distressing symptoms, ensuring comfort and dignity [62]. They facilitate discussions about advance directives and end-of-life preferences, respecting patient autonomy and cultural values [63].

Support for Dignity in Advanced PD

Maintaining dignity involves addressing physical, emotional, and spiritual needs. Nurses provide compassionate care, support patients' self-esteem, and involve them in decision-making processes. Educating families about disease progression and caregiving techniques fosters a supportive environment that honors the patient's dignity [64].

In summary, nursing interventions in PD encompass a holistic approach addressing medication management, mobility, psychosocial support, nutrition, cognitive function, and end-of-life care. Through comprehensive and patient-centered strategies, nurses play a vital role in enhancing the quality of life for individuals living with Parkinson's Disease.

2. Conclusion

Parkinson’s Disease (PD) is a complicated neurodegenerative condition that profoundly affects both motor and non-motor abilities, posing considerable obstacles in diagnosis, therapy, and care provision. The pathogenesis of Parkinson's disease is primarily caused by the loss of dopaminergic neurons in the substantia nigra, leading to a disturbance of basal ganglia circuits. The participation of additional neurotransmitter systems, including serotonergic, noradrenergic, and cholinergic pathways, underscores the complex interaction of biochemical and anatomical alterations that form the basis of the disease's many symptoms. This complexity requires a comprehensive approach to treatment and care.

Motor dysfunction, characteristic of Parkinson's disease, presents as bradykinesia, stiffness, tremor, and postural instability, significantly diminishing patients' quality of life. The symptoms are mostly due to dopamine depletion, but are intensified by the interaction of non-dopaminergic systems. Non-motor symptoms, including as cognitive deterioration, emotional problems, autonomic dysfunction, and speech

difficulties, exacerbate the illness burden. The Unified Parkinson's Disease Rating Scale (UPDRS) and other diagnostic instruments are essential for evaluating symptom intensity and progression, assisting doctors in customizing treatment approaches.

Nursing interventions are essential in the management of Parkinson's Disease, including medication administration, mobility assistance, psychological support, dietary counseling, and palliative care. Ensuring compliance with dopaminergic medications, treating motor problems such dyskinesia, and mitigating adverse effects are essential aspects of nursing care. Strategies for mobility and fall prevention, encompassing physical therapy and home modifications, are crucial for preserving patient autonomy and safety. Psychosocial assistance, designed to mitigate sadness, anxiety, and social isolation, emphasizes the necessity of treating the emotional and mental health requirements of both patients and caregivers.

The incorporation of lifestyle alterations, especially physical activity and nutritional changes, improves symptom management and may aid in neuroprotection. Interventions aimed at cognitive and communicative deficits, including speech therapy and cognitive stimulation, tackle essential components of quality of life that frequently deteriorate in the advanced stages of Parkinson's disease. As the illness advances, palliative care becomes greater significance, emphasizing symptom alleviation, dignity, and comfort during the later stages. Nurses are essential in coordinating interdisciplinary treatment, advocating for patients, and offering information and support to caregivers, so promoting a comprehensive approach to disease management.

Notwithstanding considerable progress in comprehending Parkinson's Disease, numerous problems persist, such as early identification, efficient care of non-motor symptoms, and the creation of disease-modifying medications. Recent investigations into biomarkers, genetic determinants, and neuroprotective approaches show potential for revolutionizing Parkinson's disease treatment. The investigation of novel therapeutics, including deep brain stimulation and gene therapy, provides optimism for enhancing outcomes and decelerating disease development.

In summary, Parkinson's Disease necessitates a holistic and multidisciplinary strategy that integrates medicinal, rehabilitative, and psychological interventions to tackle its intricate and progressing characteristics. Nurses, as essential members of the healthcare team, are crucial in providing patient-centered care, advocating for quality of life, and assisting families and caregivers across the disease continuum. Ongoing research and collaborative initiatives are crucial for enhancing care, mitigating the disease's impact, and ultimately increasing the quality of life for persons afflicted with Parkinson's Disease.

References

Parkinson J. An Essay on the Shaking Palsy. 1817.

Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912.

Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435-450.

Dorsey ER, Elbaz A, Nichols E, et al. Global, regional, and national burden of Parkinson's

disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-953.
Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583-1590.
Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord. 2013;28(3):311-318.
Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord. 2008;23 Suppl 3.
Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014;29(5):634-650.
Del Tredici K, Braak H. Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol. 2016;42(1):33-50.
Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci and causal insights for Parkinson's disease through a meta-analysis of genome-wide association studies. Nat Genet. 2019;51(2):199-208.
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257-1272.
Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018;33(8):1248-1266.
Keus SHJ, Munneke M, Graziano M, et al. European Physiotherapy Guideline for Parkinson's Disease. 2014.
van der Marck MA, Bloem BR. How to organize multispecialty care for patients with Parkinson's disease. Parkinsonism Relat Disord. 2014;20 Suppl 1
Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017;32(9):1264-1310.
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912.
DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007;64(1):20-24.
Politis M, Wu K, Loane C, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest. 2014;124(3):1340-1349.
Pagano G, Niccolini F, Politis M. Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies. Ann Neurol. 2017;81(2):171-180.
Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J Neurol Neurosurg Psychiatry. 2013;84(7):774-783.
Rommelfanger KS, Weinshenker D. Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem Pharmacol. 2007;74(2):177-190.
Bohnen NI, Müller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73(20):1670-1676.
Yarnall AJ, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov Disord. 2011;26(14):2496-2503.
Mollenhauer B, Caspell-Garcia CJ, Coffey CS, et al. Longitudinal analyses of cerebrospinal fluid α-synuclein in prodromal and early Parkinson's disease. Mov Disord. 2020;35(8):1289–1300.
Simuni T, Uribe L, Cho HR, et al. Clinical and biochemical correlates of baseline CSF α-synuclein in the Parkinson's Progression Markers Initiative (PPMI) cohort. J Neurol Neurosurg Psychiatry. 2020;91(7):662–668.
Angelova PR, Abramov AY. Role of mitochondrial ROS in the brain: From physiology to neurodegeneration. FEBS Lett. 2018;592(5):692–702.
Domingues HS, Portugal CC, Socodato R, Relvas JB. Oligodendrocyte, astrocyte, and

microglia crosstalk in myelin development, damage, and repair. Front Cell Dev Biol. 2016;4:71.
Chang D, Nalls MA, Hallgrímsdóttir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet. 2017;49(10):1511–1516.
Zhang M, Gao L, Zhang J, et al. The role of inflammation in Parkinson's disease. Front Aging Neurosci. 2021;13:650144.
Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1)
–S8.
Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.
Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain. 2001;124(Pt 11):2131–2146.
Louis ED, Machado DG. Tremor-related quality of life: a comparison of essential tremor vs. Parkinson's disease patients. Parkinsonism Relat Disord. 2015;21(7):729–735.
Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson's disease. J Neurol. 2001;248(11):950–958.
Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord. 2008;23 Suppl 3
–S559.
DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007;64(1):20–24.
Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014;29(5):634–650.
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–442.
Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–148.
Morris ME, Iansek R, Matyas TA, Summers JJ. Stride length regulation in Parkinson's disease. Normalization strategies and underlying mechanisms.
Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord. 2005;20(11):1502–1507.
Daley DJ, Myint PK, Gray RJ, Deane KH. Systematic review on factors associated with medication non-adherence in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(10):1053–1061.
Hauser RA, Auinger P. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord. 2011;26(5):813–818.
Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009;24(6):826–832.
Keus SH, Munneke M, Graziano M, et al. European Physiotherapy Guideline for Parkinson's Disease. KNGF/ParkinsonNet. 2014.
Tomlinson CL, Patel S, Meek C, et al. Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis. BMJ. 2012;345.
Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson's disease: a systematic review. Parkinsons Dis. 2013;2013:906274.
Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson's disease. J Neurol. 2001;248(11):950–958.
Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-

motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245.

Ellis T, Boudreau JK, DeAngelis TR, et al. Barriers to exercise in people with Parkinson disease. Phys Ther. 2013;93(5):628–636.

Mosley PE, Moodie R, Dissanayaka NN. Caregiver burden in Parkinson disease: a critical review of recent literature. J Geriatr Psychiatry Neurol. 2017;30(5):235–252.

Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2003;2(2):107–116.

Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord. 2014;20(5):535–540.

Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology. 2011;77(3):288–294.

Schenkman M, Hall DA, Barón AE, et al. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther. 2012;92(11):1395–1410.

Emre M, Ford PJ, Bilgiç B, Uç EY. Cognitive impairment and dementia in Parkinson's disease: practical issues and management. Mov Disord. 2014;29(5):663–672.

Goldman JG, Vernaleo BA, Camicioli R, et al. Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. NPJ Parkinsons Dis. 2018;4:19.

Ramig LO, Fox C, Sapir S. Speech treatment for Parkinson's disease. Expert Rev Neurother. 2008;8(2):297–309.

Miller N, Noble E, Jones D, Burn DJ. Life with communication changes in Parkinson's disease. Age Ageing. 2006;35(3):235–239.

Kluger BM, Fox S, Timmons S, et al. Palliative care and Parkinson's disease: meeting summary and recommendations for clinical research. Parkinsonism Relat Disord. 2017;37:19–26.

Hassan A, Wu SS, Schmidt P, Simuni T, Malaty IA, Okun MS. What matters most to people with Parkinson's disease? National survey of patients and caregivers. Neurology. 2012;79(20):2006–2008.

Richfield EW, Jones EJ, Alty JE. Palliative care for Parkinson's disease: a summary of the evidence and future directions. Palliat Med. 2013;27(9):805–810.